

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

New formation of imines of C₁₉-diterpenoid alkaloids by heating with DMSO

Ya-Mei He^a; Chun-Lan Zou^a; Qiao-Hong Chen^a; Feng-Peng Wang^a

^a Department of Chemistry of Medicinal Natural Products, West China College of Pharmacy, Sichuan University, Chengdu, China

To cite this Article He, Ya-Mei , Zou, Chun-Lan , Chen, Qiao-Hong and Wang, Feng-Peng(2007) 'New formation of imines of C₁₉-diterpenoid alkaloids by heating with DMSO', Journal of Asian Natural Products Research, 9: 8, 713 — 720

To link to this Article: DOI: 10.1080/10286020600979803

URL: <http://dx.doi.org/10.1080/10286020600979803>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

New formation of imines of C₁₉-diterpenoid alkaloids by heating with DMSO

YA-MEI HE, CHUN-LAN ZOU, QIAO-HONG CHEN and FENG-PENG WANG*

Department of Chemistry of Medicinal Natural Products, West China College of Pharmacy, Sichuan University, No. 17, Duan 3, Renmin Nan Road, Chengdu 610041, China

(Received 23 March 2006; revised 29 June 2006; in final form 5 July 2006)

Treatment of some C₁₉-diterpenoid alkaloids (**3**, **6**, **10** and **12**) with anhydrous DMSO at 100–170°C for 3–7 h led to the formation of the corresponding imines (**4**, **7/8**, **11**, **13/14**) in 65–83% yield, respectively. This is a new simpler formation of the imines of the C₁₉-diterpenoid alkaloids.

Keywords: Imine formation; C₁₉-Diterpenoid alkaloid; Dimethyl sulphoxide Talatisamine

1. Introduction

In our continuing investigation on the chemistry of diterpenoid alkaloids [1], displaying a lot of interesting chemistry [2,3] and important biological activities, an attempt to carry out the Wagner–Meerwein rearrangement of compound **1** using DMSO led, surprisingly, to the imine **2**, which is a new preparation of imines of the C₁₉-diterpenoid alkaloids. Preparation methods of imines of C₁₉-diterpenoid alkaloids have been summarised, including oxidation with CrO₃/pyridine [4], KMnO₄ [5], Pb (OAc)₄ [6], or NBS [7–10], rearrangement of chloroamines [11] as well as heating some oxazolidine-containing or having *O*, *N*-mixed acetal diterpenoid alkaloids with Ac₂O-Pyridine [2,12,13]. However, most of them, except for the NBS method reported by us, are not very useful owing to low yields [8,9] or structurally limited substrates. Therefore, application of DMSO to the conversion of amines in the C₁₉-diterpenoid alkaloids into imines is worthy of further research. In 1994, Jinbo *et al.* [14] reported the oxidation of secondary amines to imines using activated DMSO. Interestingly, this conversion for the tertiary amines such as the C₁₉-diterpenoid alkaloids using only DMSO rather than activated DMSO reagent has not yet been reported. Thus, we have found a useful method for the formation of imines of C₁₉-diterpenoid alkaloids by heating with dry DMSO. In order to observe the application of preparation of imines by DMSO mentioned above, we focused our attention on the different C₁₉-diterpenoid alkaloids and the optimisation of the reaction conditions. In this paper, we wish to report the preparation of imines of C₁₉-diterpenoid alkaloids by heating with dry DMSO.

*Corresponding author. Email: wfp@wcums.edu.cn

2. Results and discussion

Since 1980, many studies on the chemistry of diterpenoid alkaloids have been carried out in our laboratory. During these studies, we found that heating **1** with DMSO yielded the unexpected imine **2**. While treatment of compound **3** with DMSO at 100–140°C for 12 h also afforded the imine **4** in 56% yield besides the minor immonium salt **5** (16%). Compound **4**, C₂₂H₃₃NO₅ (HRMS), was obtained as amorphous powder. Its ¹H NMR and ¹³C NMR spectra showed the typical imine signals at δ_H 8.80 (br s) and δ_C 165.2 (d) and the absence of an *N*-ethyl group. Based on these interesting results, we turned our attention to observation of the reaction, including optimisation of the reaction conditions, the limitation for preparation of the imines of C₁₉-diterpenoid alkaloids.

Preliminary trials under various conditions (table 1) showed that treatment of **3** with dry DMSO at 130°C for 3 h afforded **4** in 82% yield (table 1). The imines could be achieved in excellent yields (65–83%) by heating the substrates (**3**, **6**, **10**, **12**) with dry DMSO at the temperature and for the time shown in table 1. It is quite interesting that the C₁₉-diterpenoid alkaloids having substituent groups at C-3 and C-6, e.g., 3-acetylyunaconitine (**15**), afforded only the *N*-deethyl compounds, probably due to the hindrance of the substitutions at C-3 and C-6. Therefore, this method of formation of imines is obviously more adequate to the C₁₉-diterpenoid alkaloids without substitutions at C-3 and C-6.

It is worth noting that, in this case, the conversion of the tertiary amines (**3**, **6**, **10**, **12**) to the imines (**4**, **7**, **11**, **13**) possibly undergo a process different from that reported by Jinbo *et al.* [14]. Considering the general mechanism for oxidation of alcohols or secondary amines using activated DMSO [15,16], we postulate a process of formation of the imines of the C₁₉-diterpenoid alkaloids (figure 1). First, a nucleophilic attack of the lone-pair electron of the nitrogen atom on the sulphur atom in DMSO [15] led to the intermediate B which produced C by a β-elimination with loss of ethylene, while α-elimination of C afforded the imines D and the intermediate E. The latter was subjected again to an electron transference depicted in figure 1 to regenerate DMSO together with release of methylsulphide via dehydration. The methylsulphide formed by treatment of talatisamine (**3**) with DMSO at 130°C was collected and identified on the basis of its disagreeable odour and distinct signal at δ_H 2.11 (6H, s) in the ¹H NMR spectrum [17]. In addition, the key intermediate B also produced the immonium salt F and the *N*-deethyl compound G through α-elimination and electron transference as shown in figure 1, respectively.

Table 1. Reaction with anhydrous DMSO.

Entry	Substrate	Reagent	Temperature (°C)	Time (h)	Product (yield %)
1	1	DMSO†	138	5	2 (21%)
2	Talatisamine (3)	DMSO†	100–140	12	4 (56%), 5 (16%)
3	Talatisamine (3)	Dry DMSO + EtOAc	120	6	4 (35%)
4	Talatisamine (3)	Dry DMSO	100–130	3	4 (65%), 5 (33%)
5	Talatisamine (3)	Dry DMSO	130	3	4 (82%), 5 (13%)
6	14-Acetyltalatisamine (6)	Dry DMSO	130	6‡	7 (69%), 8 (11%), 9 (15%)
7	8,14-Diacetyltalatisamine (10)	Dry DMSO	100	6‡	11 (83%)
8	Lappaconitine (12)	Dry DMSO	100	2	13 (65%), 14 (15%)
9	3-Acetylyunaconitine (15)	Dry DMSO	150	3	16 (68%)
10	Deltaline (17)	Dry DMSO	170	3	18 (56%)

† No steamed treatment.

‡ The reaction has not finished after 3 h.

In summary, the imines of diterpenoid alkaloids can be prepared in excellent yields by heating with dry dimethyl sulphoxide (DMSO) at 100–170°C for 3–7 h. To the best of our knowledge, this method provided the most simple and convenient preparation of the imines of C₁₉-diterpenoid alkaloids. Further studies on the utilisation of the method for other different substrates besides the diterpenoid alkaloids are currently in progress.




Figure 1. Structures of compounds 1–18.




Figure 2. A possible mechanism for formation of compounds **2**, **4**, **6**, **7**, **11**, **13**, **14**, **16**, and **18**.

3. Experimental

3.1 General experimental procedures

Melting points were determined on a Kofler block and are uncorrected; optical rotations were measured in a 1.0 dm cell with a Jasco Dip-370 polarimeter at $20 \pm 1^\circ\text{C}$; IR spectra were recorded on a Nicolet 200 SXV spectrometer; MS spectra were obtained with a Finnigan LCQ and Micromass Auto Spec Ultima-Tof spectrometer; ^1H NMR and ^{13}C NMR spectra were acquired on a Bruker AC-E 200 or a Varian INOVA-400/54 spectrometer, with TMS as internal standard; Silica GF₂₅₄ and gel H (10–40 μm , Qingdao Sea Chemical Factory, China) were used for TLC and CC. Only key signals for all products in the ^1H NMR spectra are reported.

3.2 Substrate preparation

3.2.1 Compound 1. **1** was prepared from talatisamine (**3**) by TsCl. 1: δ_{H} (200 MHz, CDCl_3): 1.07 (3H, t, $J = 7.0$ Hz, NCH_2CH_3), 3.11 (3H, s, SO_2CH_3), 3.27, 3.29, 3.30 (each 3H, s, $\text{OCH}_3 \times 3$), 4.93 (1H, t, $J = 4.9$ Hz, H-14 β); δ_{C} (50 MHz, CDCl_3): 85.1 (C-1), 26.0 (C-2), 32.1 (C-3), 38.3 (C-4), 38.5 (C-5), 25.0 (C-6), 44.5 (C-7), 73.4 (C-8), 46.3 (C-9), 45.4 (C-10), 48.8 (C-11), 28.4 (C-12), 46.1 (C-13), 81.6 (C-14), 40.9 (C-15), 82.5 (C-16), 61.8 (C-17), 79.3 (C-18), 53.1 (C-19), 49.4 (C-21), 13.3 (C-22), 56.0 (C-1'), 56.0 (C-16'), 58.3 (C-18'), 38.9 (SO_2CH_3); (EI-MS) m/z : 499 (2, M^+), 484 (5), 468 (100).

3.2.2 Compounds. **3** [18], **6** [18], **10** [20], **12** [19], **15** [20], and **17** [20] were separated or prepared by our laboratory.

Table 2. ¹³C NMR data of compounds **2**, **4**, **5**, **7**, **8**, **9**, and **11**.

No.	2	4	5	7	8	9	11
1	81.2	83.3	80.2	81.0	75.6	80.0	82.4
2	26.8	25.5	19.9	24.3	23.5	19.4	23.5
3	23.8	27.1	28.3	28.2	32.3	29.2	29.6
4	48.8	47.6	48.0	49.3	47.9	47.5	48.5
5	38.9	37.3	37.7	35.8	35.3	37.1	40.8
6	25.2	27.1	24.9	26.9	27.1	24.4	26.4
7	41.0	39.3	39.4	41.4	41.3	39.4	39.4
8	72.8	72.3	72.2	73.1	73.3	72.3	75.2
9	53.4	42.6	38.3	41.6	44.6	37.4	41.0
10	44.2	52.4	53.7	53.2	49.2	54.1	49.2
11	49.0	42.9	42.7	44.8	49.4	43.1	44.2
12	28.3	25.6	24.2	25.0	24.5	23.9	24.4
13	44.9	46.2	42.5	44.0	43.6	42.1	47.9
14	81.9	84.7	81.7	83.2	83.2	81.7	85.0
15	40.5	37.5	39.6	40.3	129.6	37.1	38.7
16	82.6	75.4	84.5	76.2	131.1	75.4	75.5
17	61.7	62.7	67.6	62.1	62.7	66.8	61.6
18	75.5	75.1	73.1	75.6	75.6	73.0	75.5
19	164.3	165.2	178.2	164.5	164.6	177.4	164.1
21	–	–	55.9	–	–	55.8	–
22	–	–	13.6	–	–	13.4	–
1-OCH ₃	55.9	56.1	56.3	55.8	55.9	56.2	56.1
16-OCH ₃	56.1	56.5	56.4	55.8	–	56.2	56.5
18-OCH ₃	59.4	59.5	59.4	59.4	59.3	56.3	59.5
8-OAC	–	–	–	–	–	–	170.8
–	–	–	–	–	–	–	21.2
14-OAC	–	–	–	170.6	170.1	170.8	169.1
–	–	–	–	21.2	21.0	21.2	22.2
SO ₂ CH ₃	–	–	–	–	–	–	–

3.3 Treatment of C₁₉-diterpenoid alkaloids with DMSO: general procedure for table 1

To a solution of the C₁₉-diterpenoid alkaloids (0.17–0.20 mmol) dry DMSO (1 ml) was added and the reaction mixture was heated at the temperature and for the time shown in table 1. After evaporation in a vacuum, the residue was subjected to column chromatography on silica gel (CHCl₃/MeOH) to give the pure product.

3.4 Reactions for table 1

3.4.1 Compound 2. Compound **1** [18] (260 mg, 0.52 mmol) and DMSO (12 ml) gave **2** (50 mg, 21%).

Compound **2**: *R*_f (95% CHCl₃/CH₃OH) 0.36; [α]_D²⁰ = +14.9 (*c* 0.5, CHCl₃); δ_H (200 MHz, CDCl₃) 3.10 (3H, s, SO₂CH₃), 3.18, 3.29, 3.32 (each 3H, s, OCH₃ × 3), 4.93 (1H, t, *J* = 4.8 Hz, H-14β), 7.19 (1H, s, H-19); δ_C (50 MHz, CDCl₃), see table 2; *m/z* (ESI) 470 (3, [M + H]⁺), 454 (15, M-CH₃), 440 (32), 424 (46); HRESI-MS *m/z* 470.2207 [M + H]⁺ (calcd for C₂₃H₃₆NO₇S, 470.2204).

3.4.2 Compounds 4 and 15. Talatisamine (**3**) (100 mg, 0.24 mmol) and dry DMSO (1 ml) gave **4** (76 mg, 82%), **5** (13 mg, 13%) as amorphous powder and methylsulphide (7 mg, colourless liquid).

Compound **4**: Mp 96–97°C; *R*_f (95% CHCl₃/CH₃OH) 0.44; α_D²⁰ = +21.3 (*c* 0.95, CHCl₃); δ_H (400 MHz, CDCl₃) 3.21, 3.34, 3.39 (each 3H, s, OCH₃ × 3), 7.27 (1H, br s, H-19);

δ_{C} (50 MHz, CDCl_3), see table 2; m/z (ESI) 392 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 392.2415 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{22}\text{H}_{34}\text{NO}_5$, 392.2431).

Compound **5**: Mp 99–100°C; R_{f} (83% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.37; $\alpha_{\text{D}}^{20} = -12.0$ (c 1.2, CHCl_3); δ_{H} (400 MHz, CDCl_3) 1.48 (3H, t, $J = 7.2$ Hz, NCH_2CH_3), 3.23, 3.38, 3.41 (each 3H, s, $\text{OCH}_3 \times 3$), 4.22 (1H, t, $J = 4.7$ Hz, H-14 β), 8.80 (1H, br s, H-19); δ_{C} (50 MHz, CDCl_3), see table 2; m/z (EI) 420 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 420.5626 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{24}\text{H}_{38}\text{NO}_5$, 420.5679).

Methylsulphide: liquid with strong disagreeable odour. δ_{H} (400 MHz, CDCl_3) 2.11 (6H, s).

3.4.3 Compounds 7, 8, and 9. 14-Acetylaltatisamine (**6**) (100 mg, 0.22 mmol) and dry DMSO (1 ml) gave **7** (65 mg, 69%), **8** (10 mg, 11%), and **9** (15 mg, 15%).

Compound **7**: Mp 103–104°C; R_{f} (95% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.43; $\alpha_{\text{D}}^{20} = +52.9$ (c 1.55, CHCl_3); δ_{H} (400 MHz, CDCl_3) 2.06 (3H, s, 14-OAc), 3.22, 3.25, 3.35 (each 3H, s, $\text{OCH}_3 \times 3$), 4.85 (1H, t, $J = 4.8$ Hz, H-14 β), 7.23 (1H, br s H-19); δ_{C} (50 MHz, CDCl_3), see table 2; m/z (ESI) 434 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 434.2551 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{24}\text{H}_{36}\text{NO}_6$, 434.2537).

Compound **8**: Mp 107–108°C; R_{f} (95% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.37; $\alpha_{\text{D}}^{20} = +48.3$ (c 1.0, CHCl_3); δ_{H} (400 MHz, CDCl_3) 2.04 (3H, s, 14-OAc), 3.20, 3.36 (each 3H, s, $\text{OCH}_3 \times 2$), 4.86 (1H, t, $J = 4.8$ Hz, H-14 β), 5.69 (1H, dd, $J = 7.6$, 2 Hz, H-15), 5.90 (1H, d, $J = 8$ Hz, H-16), 7.24 (1H, br s H-19); δ_{C} (50 MHz, CDCl_3), see table 2; m/z (ESI) 402 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 402.2266 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{23}\text{H}_{32}\text{NO}_5$, 402.2275).

Compound **9**: Mp 99–101°C; R_{f} (83% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.35; $\alpha_{\text{D}}^{20} = -10.4$ (c 0.5, CHCl_3); δ_{H} (400 MHz, CDCl_3) 1.49 (3H, t, $J = 7.2$ Hz, NCH_2CH_3), 2.07 (3H, s, 14-OAc), 3.17, 3.32, 3.41 (each 3H, s, $\text{OCH}_3 \times 3$), 4.39 (1H, d, $J = 6.8$ Hz, H-6 β), 4.86 (1H, t, $J = 4.8$ Hz, H-14 β), 8.69 (1H, br s H-19); δ_{C} (50 MHz, CDCl_3), see table 2; m/z (ESI) 430 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 430.2603 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{25}\text{H}_{36}\text{NO}_5$, 430.2588).




3.4.4 Compound 11. 8,14-Acetylaltatisamine (**10**) (100 mg, 0.2 mmol) and dry DMSO (1 ml) gave **11** (78 mg, 83%).

Compound **11**: Mp 88–89°C; R_{f} (97% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.52; $\alpha_{\text{D}}^{20} = +64.5$ (c 1.1, CHCl_3); δ_{H} (400 MHz, CDCl_3) 1.90, 2.01 (each 3H, s, OAc $\times 2$), 3.20, 3.31, 3.31 (each 3H, s, $\text{OCH}_3 \times 3$), 4.79 (1H, t, $J = 4.6$ Hz, H-14 β), 7.14 (1H, br s, H-19); δ_{C} (50 MHz, CDCl_3), see table 2; m/z (ESI) 476 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 476.2637 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{26}\text{H}_{38}\text{NO}_7$, 476.2643).

3.4.5 Compounds 13 and 14. Lappaconitine (**12**) [19] (100 mg, 0.17 mmol) and dry DMSO (1 ml) gave **13** (59 mg, 65%) and **14** (10 mg, 15%).

Compound **13**: Mp 105–106°C; R_{f} (95% $\text{CHCl}_3/\text{CH}_3\text{OH}$) 0.31; $\alpha_{\text{D}}^{20} = +52.4$ (c 1.0, CHCl_3); δ_{H} (400 MHz, CDCl_3) 2.18 (3H, s, OAc), 3.22, 3.31, 3.41 (each 3H, s, $\text{OCH}_3 \times 3$), 7.03 (1H, t, $J = 7.4$ Hz, H-5'), 7.52 (1H, t, $J = 7.3$ Hz, H-4'), 7.96 (1H, d, $J = 8.0$ Hz, H-3'), 8.68 (1H, d, $J = 8.4$ Hz, H-6'), 11.0 (1H, br s, NHAc); δ_{C} (50 MHz, CDCl_3), see table 3; m/z (ESI) 554 (100, $[\text{M} + \text{H}]^+$); HRESI-MS m/z 554.5948 $[\text{M} + \text{H}]^+$ (calcd for $\text{C}_{30}\text{H}_{38}\text{N}_2\text{O}_8$, 554.5956).

Table 3. ¹³C NMR data of compounds **13**, **14**, **16**, and **18**.

No.	13	14	16	18	No.	13	14	16	18
1	82.3	82.7	80.3	81.3	18-OCH ₃	–	–	58.8	56.1
2	23.2	19.5	31.7	26.9		169.0	–	–	–
3	27.0	29.6	71.6	39.2		25.5	–	–	–
4	88.6	77.1	49.9	33.8		167.1	–	–	–
5	48.1	46.8	48.2	50.2					
6	26.9	29.1	81.8	28.8	1	141.8	–	–	–
7	41.3	42.3	42.3	91.7	2'	115.1	–	–	–
8	75.4	75.1	73.7	81.4	3'	120.2	–	–	–
9	88.0	76.5	47.0	49.9	4'	134.7	–	–	–
10	36.8	36.5	45.4	83.8	5'	122.3	–	–	–
11	53.8	54.7	42.6	55.8	6'	130.8	–	–	–
12	26.9	27.5	40.6	34.5	3-OAc	–	–	170.2	–
13	52.4	30.7	76.8	43.7		–	–	21.1	–
14	89.7	88.8	82.0	81.5	6-OAc	–	–	–	169.7
15	44.2	35.3	129.8	36.3		–	–	–	21.3
16	81.3	81.0	134.8	77.5	14-OAs	–	–	113.9	–
17	62.1	68.9	63.7	64.9		–	–	113.9	–
18	–	–	71.9	25.5		–	–	131.7	–
19	159.2	176.3	50.3	59.4		–	–	131.7	–
21	–	57.1	–	–		–	–	163.9	–
22	–	12.6	–	–		–	–	167.0	–
1-OCH ₃	56.2	56.3	56.6	55.7		–	–	55.4	–
6-OCH ₃	–	–	57.6	57.6		–	–	–	93.8
14-OCH ₃	56.4	56.3	–	–					
16-OCH ₃	57.9	57.1	–	–					

Compound **14**: Mp 99–100°C; *R_f* (83% CHCl₃/CH₃OH) 0.33; $\alpha_D^{20} = -50.9$ (*c* 1.25, CHCl₃); δ_H (400 MHz, CDCl₃) 1.50 (3H, t, *J* = 7.2 Hz, NCH₂CH₃), 3.17, 3.34, 3.44 (each 3H, s, OCH₃ × 3), 8.59 (1H, br s, H-19); δ_C (50 MHz, CDCl₃) see Table 3; *m/z* (ESI) 422 (100, [M + H]⁺); HRESI-MS *m/z* 422.5067 [M + H]⁺ (calcd for C₂₃H₃₆NO₆, 422.5081).

3.4.6 Compound 16. 3-Acetyluonaconitine (**15**) (100 mg, 0.14 mmol) and dry DMSO (1 ml) gave **16** (62 mg, 68%).

Compound **16**: Mp 152–153°C; *R_f* (95% CHCl₃/CH₃OH) 0.35; $\alpha_D^{20} = +66.9$ (*c* 0.95, CHCl₃); δ_H (400 MHz, CDCl₃) 2.06 (3H, s, 3-OAc), 3.23, 3.23, 3.35, 3.86 (each 3H, s, OCH₃ × 4), 4.90 (1H, dd, *J* = 5.6, 6.8 Hz, H-3), 5.18 (1H, dd, *J* = 2.0, 4.8 Hz, H-14β), 5.59 (1H, dd, *J* = 2.0, 7.6 Hz, H-15), 5.90 (1H, d, *J* = 9.6 Hz, H-16), 6.92 ~ 7.91 (Ar-H); δ_C (50 MHz, CDCl₃), see table 3; *m/z* (ESI) 599 (5, [M + H]⁺), 628 (100); HRESI-MS *m/z* 599.6758 [M + H]⁺ (calcd for C₃₂H₄₁NO₁₀, 599.6766).

3.4.7 Compound 18. Deltaline (**17**) (100 mg, 0.2 mmol) and dry DMSO (1 ml) gave **18** (53 mg, 52%).

Compound **18**: Mp 193–194°C; R_f (97% CHCl₃/CH₃OH) 0.47; $\alpha_D^{20} = -17.8$ (c 1.2, CHCl₃), C₂₅H₃₆NO₈, δ_H (400 MHz, CDCl₃) 0.88 (3H, t, 18-CH₃), 2.07 (3H, s, 6-OAc), 3.28, 3.32, 3.44 (each 3H, s, OCH₃ × 3), 4.12 (1H, t, $J = 4.8$ Hz, H-14 β); δ_C (50 MHz, CDCl₃), see table 3; m/z (ESI) 480 (4, [M + H]⁺); HRESI-MS m/z 480.5255 [M + H]⁺(calcd for C₂₅H₃₇NO₈, 480.5260).

Acknowledgements

Financial support for this research was provided by the National Natural Science Foundation of China (No. 30472075). We also thank Professor Xiao-Tian Liang, Institute of Materia Medica, Chinese Academy of Sciences, Beijing, for helpful discussion on the manuscript.

References

- [1] (a) F.P. Wang, X.T. Liang. *Tetrahedron*, **42**, 265 (1986). (b) F.P. Wang, J.Z. Wang, R. Zhang. *Heterocycles*, **45**, 659 (1997). (c) F.P. Wang, J.S. Yang, Q.H. Chen, L. Yu, B.G. Li. *Chem. Pharm. Bull.*, **48**, 1912 (2000). (d) F.P. Wang, Q.H. Chen, B.G. Li. *Tetrahedron*, **42**, 4705 (2001)
- [2] F.P. Wang, X.T. Liang. The alkaloids: chemistry and biology. In *Chemistry of Diterpenoid Alkaloids*, G.A. Cordell (Ed.), **Vol. 42**, pp. 152–247, Academic, New York (1992).
- [3] F.P. Wang, X.T. Liang. The alkaloids: chemistry and biology. In *C₂₀-Diterpenoid Alkaloids*, G.A. Cordell (Ed.), **Vol. 59**, pp. 1–280, Elsevier, New York, NY (2002).
- [4] S.W. Pelletier, P.C. Pathasarathy. *Am. J. Chem. Soc.*, **87**, 777 (1965).
- [5] de La G. Fuente, Rwiz L. Mesia. *Phytochemistry*, **39**, 1459 (1995).
- [6] J.J. Nie. MS Thesis, Kuming Institute of Botany, Chinese Academy of Sciences, 20 (1996).
- [7] F.P. Wang, Z.B. Li, J.S. Yang, B.G. Li. *Chin. Chem. Lett.*, **10**, 453 (1999).
- [8] (a) F.P. Wang, Z.B. Li, J.S. Yang, B.G. Li. *Chin. Chem. Lett.*, **10**, 153 (1999). (b) L. Xu, Q.H. Chen, F.P. Wang. *Tetrahedron*, **58**, 4267 (2000). (c) Q.H. Chen, L. Xu, F.P. Wang. *Tetrahedron*, **58**, 9431 (2000). (d) F.P. Wang, L. Xu. *Tetrahedron*, **11**, 2149 (2005).
- [9] Q.H. Chen, L. Xu, F.P. Wang. *Chin. Chem. Lett.*, **14**, 147 (2003).
- [10] X.L. Shen, F.P. Wang. *Chem. Pharm. Bull.*, **52**, 1095 (2004).
- [11] (a) T. Yatsunamin, T. Isona, I. Hayakawa, T. Okamoto. *Chem. Pharm. Bull.*, **23**, 3030 (1975). (b) T. Yatsunamin, S. Furuya, T. Okamoto. *Chem. Pharm. Bull.*, **26**, 3199 (1978). (c) J.Z. Fun, Z.B. Li, Q.H. Chen, F.P. Wang. *Chin. Chem. Lett.*, **11**, 417 (2000).
- [12] D. Dvornik, O.E. Edwards. *Can. J. Chem.*, **35**, 860 (1957).
- [13] D. Dvornik, O.E. Edwards. *Chem. Ind. (London)*, 952 (1957).
- [14] Y. Jinbo, H. Kondo, M. Taguchi, F. Sakamoto, G. Tsukamoto. *J. Org. Chem.*, **59**, 6057 (1994).
- [15] A.J. Mancuso, D. Swern. *Synthesis*, 165 (1981).
- [16] W.W. Epstein, F.W. Sweat. *Chem. Rev.*, **67**, 247 (1967).
- [17] E. Pretsch, P. Bühlmann, C. Affolter. *Structure Determination of Organic Compounds: Tables of Spectral Data*, (In Chinese) (Translated from the English by Guo-bin Rong), pp. 215, Press of Haido University of Technology, (2002).
- [18] F. Gao, F.P. Wang. *Heterocycles*, **65**, 365 (2005).
- [19] C.S. Peng, J.Z. Wang, X.X. Jian, F.P. Wang. *Nat. Prod. Res. Dev.*, **12**(4), 45 (2000).
- [20] F.P. Wang. Unpublished data.